

## References

I-91

1. NCCN Practice Guidelines in Oncology – Colon Cancer. V.2.2016. National Comprehensive Cancer Network (NCCN). Accessed July 14, 2016.
2. Chua TC, Liauw W, Zhao J, Morris DL. Upfront compared to delayed cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei is associated with considerably lower perioperative morbidity and recurrence rate. *Ann Surg.* 2011;253(4):769-773.
3. Esquivel J, Averbach A, Chua TC. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with limited peritoneal surface malignancies: Feasibility, morbidity and outcome in an early experience. *Ann Surg.* 2011;253(4):764-768.
4. Lammers RJ, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: A systematic review. *Eur Urol.* 2011;60(1):81-93.
5. Cashin P, Nygren P, Hellman P, Granberg D, Andréasson H, & Mahteme H. Appendiceal adenocarcinoids with peritoneal carcinomatosis treated with cytoreductive surgery and intraperitoneal chemotherapy: a retrospective study of in vitro drug sensitivity and survival. *Clin Colorectal Cancer.* 2011 Jun;10(2):108-12.
6. Deraco M, Baratti D, Laterza B, Balestra MR, Mingrone E, & Macrì A et al. Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. *Eur J Surg Oncol.* 2011 Jan;37(1):4-9.
7. Frenel JS, Leux C, Pouplin L, Ferron G, Berton Rigaud D, Bourbouloux E, Dravet F, Jaffre I, & Classe JM. Oxaliplatin-based hyperthermic intraperitoneal chemotherapy in primary or recurrent epithelial ovarian cancer: A pilot study of 31 patients. *J Surg Oncol.* 2011 Jan 1;103(1):10-6.
8. Yang, X-J, MD, Huang, C-Q, MD, Suo, T, MD. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: Final results of a phase III randomized clinical trial. *Ann Surg Oncol.* 2011 June; 18(6):1575–1581.
9. Kim M, Jung Y, Seong S. Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer. *Journal of Gynecology Oncology* April 2012; 23(2):91-97.
10. Coccolini F, Gheza F, Lotti M, et al. Peritoneal carcinomatosis. *World J Gastroenterol.* 2013;19(41):6979-6994.
11. Francescuitt V, Rivera L, Seshadri M, et al. The benefit of intraperitoneal chemotherapy for the treatment of colorectal carcinomatosis. *Oncol Rep.* 2013;30(1):35-42.
12. S DeSmet L, Ceelen W, Remon JP, et al. Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent. *ScientificWorldJournal.* 2013;720858.
13. Levine E, Stewart J, Shen P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy: Experience with 1,000 patients. *J AM Coll Surg.*2014;218(4):573-585
14. Chan DL, Morris DL, Rao A, et al. Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy. *Cancer Manag Res.* 2012;4:413–422

15. Blackham A, Levine E. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma. *European J Clin Med Oncol.* 2012;4(2):25-32.
16. Rudloff U, Langan R, Mullinax J, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial. *Journal of Surgical Oncology* 2014;(110):275–284.
17. National Comprehensive Cancer Network (NCCN) Version 1.2016. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Accessed July 14, 2016.